Loading…
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. Humacyte, Inc. was founded in 2004 and is headquartered in Durham, North Carolina.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $2M | $-22M | $-41M | $-106M | -1313.4% | - | - |
| 2024 | $0M | $-132M | $-149M | $-100M | 282.3% | - | - |
| 2023 | $0M | $-96M | $-111M | $-76M | -817.8% | - | - |
| 2022 | $0M | $2M | $-12M | $-72M | -10.2% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 2.04 |
| Cost Of Revenue | 0 | 0 | 0 | 9.70 |
| Gross Profit | 0 | 0 | 0 | -7.66 |
| Operating Expense | 84.58 | 100.05 | 114.40 | 100.47 |
| Operating Income | -84.58 | -100.05 | -114.40 | -108.14 |
| EBITDA | 2.44 | -96.46 | -132.23 | -22.24 |
| EBIT | -5.76 | -104.18 | -139.42 | -29.58 |
| Pretax Income | -11.96 | -110.78 | -148.70 | -40.83 |
| Net Income | -11.96 | -110.78 | -148.70 | -40.83 |
| Net Income Common Stockholders | -11.96 | -110.78 | -148.70 | -40.83 |
| Total Expenses | 84.58 | 100.05 | 114.40 | 110.17 |
| Interest Expense | 6.20 | 6.60 | 9.28 | 11.25 |
| Interest Income | 2.63 | 5.47 | 4.10 | 2.59 |
| Research And Development | 63.26 | 76.55 | 88.60 | 69.30 |
| Selling General And Administration | 22.88 | 23.50 | 25.80 | 31.17 |
| Normalized EBITDA | -73.74 | -86.86 | -103.10 | -98.20 |
| Normalized Income | -88.15 | -101.18 | -119.57 | -116.80 |
| Basic EPS | -0.12 | -1.07 | -1.26 | 0 |
| Diluted EPS | -0.12 | -1.07 | -1.26 | 0 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0 | 0 | 0 | 0 |
| Total Unusual Items | 76.18 | -9.60 | -29.13 | 75.97 |
| Total Unusual Items Excluding Goodwill | 76.18 | -9.60 | -29.13 | 75.97 |
| Net Income From Continuing Operation Net Minority Interest | -11.96 | -110.78 | -148.70 | -40.83 |
| Reconciled Depreciation | 8.21 | 7.72 | 7.19 | 7.34 |
| Reconciled Cost Of Revenue | 0 | 0 | 0 | 9.70 |
| Net Interest Income | -3.57 | -1.13 | -5.17 | -8.66 |
| Net Income From Continuing And Discontinued Operation | -11.96 | -110.78 | -148.70 | -40.83 |
| Total Operating Income As Reported | -84.58 | -100.05 | -114.40 | -108.14 |
| Diluted Average Shares | 103.05 | 103.42 | 118.48 | 0 |
| Basic Average Shares | 103.05 | 103.42 | 118.48 | 0 |
| Diluted NI Availto Com Stockholders | -11.96 | -110.78 | -148.70 | -40.83 |
| Net Income Including Noncontrolling Interests | -11.96 | -110.78 | -148.70 | -40.83 |
| Net Income Continuous Operations | -11.96 | -110.78 | -148.70 | -40.83 |
| Other Income Expense | 76.18 | -9.60 | -29.13 | 75.97 |
| Special Income Charges | 75.77 | -9.34 | -33.05 | 37.20 |
| Other Special Charges | 0 | -0.69 | 0 | 22.27 |
| Restructuring And Mergern Acquisition | -75.77 | 10.02 | 33.05 | -59.47 |
| Gain On Sale Of Security | 0.42 | -0.26 | 3.92 | 38.77 |
| Net Non Operating Interest Income Expense | -3.57 | -1.13 | -5.17 | -8.66 |
| Interest Expense Non Operating | 6.20 | 6.60 | 9.28 | 11.25 |
| Interest Income Non Operating | 2.63 | 5.47 | 4.10 | 2.59 |
| Other Operating Expenses | -1.56 | 0 | 0 | 0 |
| General And Administrative Expense | 22.88 | 23.50 | 25.80 | 31.17 |
| Other Gand A | 22.88 | 23.50 | 25.80 | 31.17 |
| Salaries And Wages | 0 | -3.11 | 0 | 0 |
| Operating Revenue | 0 | 0 | 0 | 2.04 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Humacyte, Inc.this co. | HUMA | $182M | - | 51.25 | -1313.4% | -1.97 |
| Cartesian Therapeutics, Inc. | RNAC | $190M | - | -1.33 | 103.2% | -0.70 |
| Quantum-Si incorporated | QSI | $187M | - | 0.85 | -46.0% | -0.31 |
| KORU Medical Systems, Inc. | KRMD | $185M | - | 10.79 | -15.5% | -78.39 |
| Korro Bio, Inc. | KRRO | $182M | - |
| 2.31 |
| -228.0% |
| -1.81 |
| CVRx, Inc. | CVRX | $181M | - | 4.60 | -135.6% | -3.08 |
| AirSculpt Technologies, Inc. | AIRS | $179M | - | 1.87 | -13.3% | 32.00 |
| Stereotaxis, Inc. | STXS | $177M | - | 12.91 | -115.6% | -9.48 |
| Tonix Pharmaceuticals Holding Corp. | TNXP | $176M | - | 0.65 | -50.6% | 0.32 |
| Peer Median | - | - | 2.09 | -48.3% | -1.26 | |